Adaptive Biotechnologies Corp 8-K

What Happened

• Adaptive Biotechnologies Corporation announced its quarterly financial results for the quarter ended March 31, 2026 by issuing a press release on May 5, 2026. The company filed an SEC Form 8-K (Item 2.02) to disclose those results and attached the press release as Exhibit 99.1.

Key Details

• Filing date: May 5, 2026.
• Period covered: quarter ended March 31, 2026 (Q1 2026).
• Disclosure type: Form 8-K, Item 2.02 — Results of Operations and Financial Condition; press release attached as Exhibit 99.1.
• Filing signed by Kyle Piskel, Chief Financial Officer.

Why It Matters

• This 8-K signals that Adaptive has publicly released its latest quarterly earnings and related financial information. Investors should read the attached press release (Exhibit 99.1) or the company’s investor relations materials to see revenue, profit/loss, guidance, or operational updates that could affect the stock. The 8-K is the official, timely SEC disclosure of those quarterly results.